Degeneracy, as opposed to specificity, in immunotherapy. - Wikidata - wikimedia - TriplyDB

Degeneracy, as opposed to specificity, in immunotherapy.

Degeneracy, as opposed to specificity, in immunotherapy.

http://www.wikidata.org/entity/Q34551385

about

Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis.Degeneracy allows for both apparent homogeneity and diversification in populations Glatiramer acetate in multiple sclerosis: a review.Functional efficacy of glatiramer acetate treatment for laser-induced retinal damage in rats.Antigen-specific therapies in multiple sclerosis: going beyond proteins and peptides.Designer glycopeptides for cytotoxic T cell-based elimination of carcinomas Glatiramer acetate treatment effects on gene expression in monocytes of multiple sclerosis patients.Tumor-associated carbohydrate antigens: a possible avenue for cancer prevention.

P2860

Q24681228-0179ECD9-72BD-4288-AE47-700524564BB3 Q28673578-9B47B936-D4F3-44CA-A998-5A8E65A3028C Q31118802-E435DDC4-B5C2-46A4-8E7E-10E87E846C96 Q33325562-F644CC36-521D-46BD-B5AA-DA012990F4B1 Q36327377-576032EF-E4D2-4CFC-872F-AE79B3A2B7D2 Q36403882-8D08B561-1953-466B-824E-ED8F598F3360 Q37367956-9B51461B-AEE9-4EA8-8E28-9BDDB0B6AE17 Q46610438-2E34D02A-6159-4E2A-9C6F-096E6B6DAD2E

P2860

Degeneracy, as opposed to specificity, in immunotherapy.

http://www.wikidata.org/entity/Q34551385

description

2002 nî lūn-bûn

@nan

2002 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի մարտին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Degeneracy, as opposed to specificity, in immunotherapy.

@ast

Degeneracy, as opposed to specificity, in immunotherapy.

@en

Degeneracy, as opposed to specificity, in immunotherapy.

@nl

type

label

Degeneracy, as opposed to specificity, in immunotherapy.

@ast

Degeneracy, as opposed to specificity, in immunotherapy.

@en

Degeneracy, as opposed to specificity, in immunotherapy.

@nl

prefLabel

Degeneracy, as opposed to specificity, in immunotherapy.

@ast

Degeneracy, as opposed to specificity, in immunotherapy.

@en

Degeneracy, as opposed to specificity, in immunotherapy.

@nl

P1433

Q34551385-D684902F-8C3B-4AC1-B864-AFF2668D24C1

P1476

Q34551385-1021698D-FEE4-4819-8E3A-FFD023DCD5BC

P2860

Q34551385-030E85D2-BF88-4F3E-9482-8F3D344C54F8

Q34551385-06553FFA-759D-45F6-A845-72AC89284149

Q34551385-3E9C0824-A241-4965-949D-F2DB3A179702

Q34551385-455432FC-6B02-481F-BDEB-F08E525C2E12

Q34551385-58889FFE-9F2E-4871-AE9E-7C5126414D53

Q34551385-58AB3939-9BEE-41BB-AE59-A8F7D51E1E08

Q34551385-5C22B019-382D-431B-9142-447B3377F52A

Q34551385-70921B2B-6AC4-47B9-A3D0-42AEA5F31A22

Q34551385-7EA24AC6-2CCB-4CE3-8612-9ACC68840D0B

Q34551385-968FE811-065A-4DD0-A7F0-E3162C0AA213

P304

Q34551385-3FF15B14-A4C2-4A86-8E90-3234B7ECE330

P31

Q34551385-F9F57B6B-9077-4047-AC05-08BDE565A5C8

P356

Q34551385-58C6D399-EA4F-48D6-97B7-F87C44C9D007

P407

Q34551385-E927E71E-9760-4F89-ABBA-2A3C1621815B

P433

Q34551385-C244CFC4-F1F2-461C-B328-B439C08B8E42

P478

Q34551385-5A664847-6003-4B0F-9A8E-C7CFBD03C2FB

P50

Q34551385-1C21AF8F-A8B9-4EEF-9F70-31C24134AF62

P577

Q34551385-F7D009AE-21A4-49A7-887A-C88AF4404819

P698

Q34551385-F7EF31C8-0725-4B74-8BCF-3E812A6F22C6

P921

Q34551385-2F1243BD-E51A-4419-B44C-D29140AA7577

P932

Q34551385-5885FEEF-0150-44C3-903F-53F83722F133

P356

P1433

Journal of Clinical Investigation

P1476

Degeneracy, as opposed to specificity, in immunotherapy.

@en

P2860

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis.

Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein.

Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis.

Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis

Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells

Identification of high potency microbial and self ligands for a human autoreactive class II-restricted T cell clone.

A T cell receptor antagonist peptide induces T cells that mediate bystander suppression and prevent autoimmune encephalomyelitis induced with multiple myelin antigens.

Complementary mutations in an antigenic peptide allow for crossreactivity of autoreactive T-cell clones

Modulation of cytokine patterns of human autoreactive T cell clones by a single amino acid substitution of their peptide ligand.

P304

581-584

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI0215198

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P50

David A. Hafler

P577

2002-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11877465

http://www.w3.org/2001/XMLSchema#string

P921

P932

150898

http://www.w3.org/2001/XMLSchema#string